类风湿关节炎中JAK抑制剂疗效与安全性的相关因素:JAGUAR登记8年观察研究
基于JAGUAR多中心登记的前瞻性数据,回顾性分析435个JAK抑制剂治疗疗程。1年因疗效不足停药率23.0%、不良反应17.0%;4年分别为32.9%、19.5%。长期联用糖皮质激素与因疗效不足停药相关,年龄与因不良反应停药相关。
要点
- 长期联用糖皮质激素者因疗效不足停用JAK抑制剂的风险更高
- 年龄≥65岁者因不良反应停用JAK抑制剂的风险更高
- 1年因疗效不足和不良反应停药率分别为23.0%和17.0%
核心结论
- 在类风湿关节炎中,长期联用糖皮质激素与因疗效不足停用JAK抑制剂相关,年龄与因不良反应停用JAK抑制剂相关。
研究设计与样本
- 回顾性队列研究,使用JAGUAR多中心类风湿关节炎登记中JAK抑制剂治疗数据,共纳入435个治疗疗程。
主要发现
- 1年时因疗效不足、不良反应和其他原因停药率分别为23.0%、17.0%和2.3%;4年时分别为32.9%、19.5%和5.5%。
- 长期联用糖皮质激素与因疗效不足停药相关(p=0.007);需糖皮质激素>6个月者较≤6个月者因疗效不足停药率更高(1年29.1% vs 18.8%;4年50.5% vs 32.5%)。
- 年龄与因不良反应停药相关(p=0.003);≥65岁者较<65岁者因不良反应停药率更高(1年25.6% vs 14.5%;4年35.3% vs 17.4%)。
临床怎么用
- 对长期联用糖皮质激素的RA患者,应关注JAK抑制剂疗效不足风险并加强评估。
- 对年龄≥65岁的RA患者,应加强JAK抑制剂不良反应监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify factors associated with the effectiveness and safety of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), as reflected by treatment retention. METHODS: This retrospective cohort study used data from the JAGUAR Registry, a multicentre RA registry of JAK inhibitor treatments. At 1 and 4 years, reasons and rates of treatment discontinuation were assessed. Treatment retention was evaluated using Cox regression and Kaplan-Meier curves. Factors associated with treatment retention were analysed for the discontinuation reasons of lack of effectiveness and adverse drug reactions (ADRs). RESULTS: A total of 435 treatment episodes with JAK inhibitors (tofacitinib: 118, baricitinib: 181, upadacitinib: 80, filgotinib: 56) were included. At 1 year, discontinuation rates were: 23.0% due to lack of effectiveness, 17.0% due to ADRs and 2.3% due to other reasons. At 4 years, the corresponding discontinuation rates were: 32.9%, 19.5% and 5.5%, respectively. Chronic concomitant glucocorticoid (GC) treatment was associated with JAK inhibitor discontinuation due to lack of effectiveness (p=0.007). Discontinuation rates due to lack of effectiveness were higher in patients requiring GCs for >6 months versus ≤6 months (29.1% vs 18.8% at 1 year; 50.5% vs 32.5% at 4 years). Age was associated with JAK inhibitor discontinuation due to ADRs (p=0.003). Discontinuation rates due to ADRs were higher in patients aged ≥65 years versus <65 years (25.6% vs 14.5% at 1 year; 35.3% vs 17.4% at 4 years). CONCLUSIONS: In RA, chronic concomitant GC treatment and patient age are associated with JAK inhibitor discontinuation due to lack of effectiveness and ADRs, respectively.
引用
- Martinez-Molina C, Frade-Sosa B, Diaz-Torné C, et al. Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry. RMD Open. 2026. PMID: 42674814. doi:10.1136/rmdopen-2026-007099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。